Given co-administration of dasatinib, the efficacy of BMS-833923 was difficult to definitively demonstrate, but the addition of the SMO inhibitor resulted in prolonged responses, including one complete cytogenetic response (CCyR) in three of ten CP-CML patients previously resistant to dasatinib. This evidence concerns the gene SMO and chronic myelogenous leukemia, BCR-ABL1 positive.